The MDS Channel on VJHemOnc is supported by Bristol Myers Squibb,Gilead Oncology and Curis Inc.. This supporter has no influence over the production of the content.
Welcome to The Myelodysplastic Syndromes (MDS) Channel
Explore all things new and exciting in MDS, with exclusive insights, must-know news, and unique expert perspectives, courtesy of The MDS Channel.
Much research is underway to address the paucity of available options in MDS and many new agents, targets, and treatment approaches are in development or under investigation, such as novel HMA-based combinations, immunotherapies including magrolimab and sabatolimab, and first-in-class agents like pevonedistat. With the support of a world-leading Editorial Board, VJHemOnc brings you informative interviews, roundtable discussions, feature articles, and podcasts; a one-stop source for the key MDS news!